Csl Limited · ASX:CSL
Csl — FY2000 Earnings Presentation
22 slides from Csl's earnings presentation, 2000
Slide 1: CSL Limited
CSL Limited AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 2: Highlights 1999/00
Highlights 1999/00 • Strong Financial Performance – Sales Revenues increase 9% – EBIT increase 12% – NPAT increase 15% – R&D investment of $43.6m increase 7% – International sales - 27% of total sales AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 3: Highlights 1999/00
Highlights 1999/00 • Major Global Initiatives – ZLB acquisition – DynPort collaboration (Q Fever vaccine) – GroPep growth factors marketing rights – JRH Europe acquires UK base AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 4: Sales by Division 1999/00
Sales by Division 1999/00 $450.6m Bioplasma 31% Veterinary 10% Biosciences Pharmaceutical 19% 40% AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 5: Total Revenues
Total Revenues 504 $500 425 367 $400 $300 Million $200 $100 $0 1998 1999 2000 Year ending 30 June AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 6: Operating Profit after Tax
Operating Profit after Tax 54.4 $60 47.4 $50 40.9 $40 Million $30 $20 $10 $0 1998 1999 2000 Year ending 30 June AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 7: EBITDA
EBITDA 110.7 $120 102.4 90.1 $100 $80 Million $60 $40 $20 $0 1998 1999 2000 Year ending 30 June AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 8: R&D Investment
R&D Investment 43.6 39.1 40.8 $45 $40 $35 $30 Million $25 $20 $15 $10 $5 $0 1998 1999 2000 Year ending 30 June AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 9: Pharmaceutical Division
Pharmaceutical Division 40% AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 10: Pharmaceutical
Pharmaceutical • Strong revenue growth at 14% (excluding Factor (f)/PIIP) • Avonex® and Daivonex® PBS listed • Fluvax® – Domestic flu market growth 9% – Market share maintained ≈ 80% – Flumist® (Aviron) continues to perform well clinically, likely application for registration 2001/02 • New launches
Slide 11: Immunotherapy Convergence
Immunotherapy Convergence ACTIVE PASSIVE Traditional Preventative Plasma derived Ab • Influenza • IVIG • Q Fever • Antivenoms • HPV • Special Immunoglobulins • EBV • IgM • Periodontal Therapeutic Recombinant Ab • H.pylori • anti D MAb • ISCOM Adjuvant - CerVax-16 - Ludwig Antigens - HCV • HPV AUSTRA
Slide 12: Bioplasma Division
31% Bioplasma Division AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 13: Bioplasma
Bioplasma • Revenue growth of 8% • Domestic plasma collections increased 6% • Export revenues increased 15% • Intragam P and Albumex / 2 VI’s introduced • Marketing approval granted by TGA for Biostate (Factor VIII) • Fibrin Bandage development on track • LFO/Polish Government considers proposal • U
Slide 14: Veterinary Division
10% Veterinary Division AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 15: Veterinary
Veterinary • Strong revenue growth at 12% – Biocor revenue growth at 25% – Domestic growth in cattle and sheep vaccines • Biocor broadens product range – Cattle vaccines acquired from Bayer – Diagnostic products introduced – Global Spirovac (Leptospiral) partnering • Development continuing on Immuno
Slide 16: Biosciences Business
19% Biosciences Business AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 17: Biosciences
Biosciences • Revenue growth at 17% • Improved margins and profitability • Domestic business refocussed • Facilities upgrade – Lenexa – Denver PA • Market growth fuelled by biotech successes AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 18: ZLB - Recap
ZLB - Recap • Closure scheduled for end of August / early September • Strategic and financial leverage • Banking Syndicate in place • Immediate access to world’s largest IVIG market • Delivers global scale AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 19: ZLB - Integration
ZLB - Integration • Peter Turner and small management team relocated to Bern • Paul Bordonaro appointed Bioplasma GM • Pete DeHart (ex Alpha Therapeutics) and Jack Wood establishing US office • Bain & Co (Germany) appointed to assist in integration AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 20: Shareholder Value
Shareholder Value • Key financial focus remains creation of shareholder value • Growth and international market access – Innovation – Leverage technological advantage AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 21: R&D by Activity
R&D by Activity Maintenance & Regulatory 25% Bioplasma 25% Veterinary 12% JRH 6% Major Projects 32% AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 22: Group Results 99/00
Group Results 99/00 2000 $m 1999 $m % Growth Sales 450.6 413.5 Other Revenue 53.7 11.4 Total Revenue 504.3 424.9 18.7% Depreciation/Amortisation 33.7 33.7 EBIT 77.2 68.7 12.3% Net Interest Expense (3.4) (1.6) Pre-tax Profit 80.6 70.3 13.1% Less Tax 26.2 22.9 Net Profit 54.4 47.4 14.8% Final Dividend